Physician profile
Shaye Rawson
NPI 1093374381
$2,036.35
in general payments reported to CMS, 2019-2025
35 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $291 · 2023: $463 · 2024: $376 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,319 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.74 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $272.03 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $206.01 | 2021-2025 | |
| Abbott Laboratories | $133.25 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $132.30 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $123.58 | 2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $117.04 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.09 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $106.60 | 2021-2025 | Farxiga, Airsupra |
| Xeris Pharmaceuticals, INC. | $98.07 | 2023-2024 | Gvoke Hypopen |
| Novo Nordisk INC | $84.26 | 2021-2024 | Wegovy |
| Novartis Pharmaceuticals Corporation | $74.82 | 2022 | |
| Intuitive Surgical, INC. | $46.78 | 2023 | Da Vinci Surgical System |
| Amgen INC. | $46.27 | 2021-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $44.22 | 2021-2022 | |
| Pfizer INC. | $43.77 | 2021-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.86 | 2024 | Xifaxan, Trulance |
| Galderma Laboratories, L.P. | $34.50 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $25.57 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $24.24 | 2023 | Rexulti |
| Leo Pharma INC. | $24.11 | 2025 | Adbry |
| Janssen Biotech, INC. | $22.54 | 2025 | Tremfya |
| Genentech USA, INC. | $19.66 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $18.11 | 2025 | Valchlor |
| Ucb, INC. | $17.78 | 2025 | Bimzelx |
| Kyowa Kirin, INC. | $16.96 | 2025 | |
| Esperion Therapeutics, INC. | $16.68 | 2023 | Nexletol |
| Janssen Pharmaceuticals, INC | $16.57 | 2021 | |
| Mylan Specialty L.P. | $16.57 | 2024 | Yupelri |
| Sanofi Pasteur INC. | $15.64 | 2023 | |
| Philips North America LLC | $15.41 | 2024 | (Cm9) Amb Mon & Diag Und |
| Idorsia Pharmaceuticals US INC | $13.76 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $13.36 | 2023 | Nuzyra |
| Exact Sciences Corporation | $13.34 | 2023 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $12.30 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaye Rawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.